Potentially hazardous co-prescribing of beta-adrenoceptor antagonists and agonists in the community.
JEFF EVANS(Intermountain Healthcare), Thomas M. MacDonald(Ninewells Hospital), John L. Hayes, Brian J. Lipworth(University of Dundee)
PubMed
July 1, 1996
Cited by 10
Related Papers
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
|The Lancet Diabetes & Endocrinology|2018|340
The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel
|Annals of the Rheumatic Diseases|2010|105
35th Annual Meeting of the European Association for the Study of Diabetes
|Diabetologia|1999|86